The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High pathologic response rate of hepatic colorectal cancer metastases (HCRM) following neoadjuvant bevacizumab (Bev)-based treatment (tx).
Filippo Pietrantonio
No relevant relationships to disclose
Jorgelina Clara Coppa
No relevant relationships to disclose
Rosalba Miceli
No relevant relationships to disclose
Massimo Milione
No relevant relationships to disclose
Federica Perrone
No relevant relationships to disclose
Giuseppe Fanetti
No relevant relationships to disclose
Cotsoglou Christian
No relevant relationships to disclose
Flavia Melotti
No relevant relationships to disclose
Maria Di Bartolomeo
No relevant relationships to disclose
Vincenzo Mazzaferro
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Alessio Pellegrinelli
No relevant relationships to disclose
Claudia Bertan
No relevant relationships to disclose
Pamela Biondani
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose